Table 1:
Characteristics of the Study Cohort
| Demographic Variable Overall N=6,451 | PEx with AST N=2,518 | PEx without AST N=3,933 | p-value |
|---|---|---|---|
| Age | <0.0001 | ||
| 0–5 years | 201 (8%) | 687 (17%) | |
| 6–11 years | 650 (26%) | 1286 (33%) | |
| 12–18 years | 1667 (66%) | 1960 (50%) | |
| Gender (Female) | 1440 (57%) | 2053 (52%) | 0.0001 |
| Race/Ethnicity | <0.0001 | ||
| Caucasian | 1760 (70%) | 2916 (74%) | |
| Hispanic/Latino | 553 (22%) | 697 (18%) | |
| African American | 101 (4%) | 152 (4%) | |
| Other | 45 (2%) | 117 (3%) | |
| Unknown | 59 (2%) | 51 (1%) | |
| Insurance Status | <0.0001 | ||
| Private | 971 (39%) | 1741 (44%) | |
| Public | 1398 (56%) | 1912 (49%) | |
| Other/Unknown | 149 (6%) | 280 (7%) | |
| Pancreatic Enzyme Use (Yes) | 2396 (95%) | 3723 (95%) | 0.4 |
| Ursodiol Use (Yes) | 524 (21%) | 612 (16%) | <0.0001 |
| Insulin Use (Yes) | 537 (21%) | 578 (15%) | <0.0001 |
| IV Aminoglycoside Use (Yes) | 1755 (70%) | 2662 (60%) | 0.09 |
| Antibiotic Count* | <0.0001 | ||
| 1 | 129 (5%) | 371 (10%) | |
| 2 | 842 (33%) | 1579 (40%) | |
| ≥3 | 1547 (61%) | 1983 (50%) | |
| # of PEx in Prior 12 Months | <0.0001 | ||
| 0 | 960 (38%) | 1955 (50%) | |
| 1 | 656 (26%) | 1000 (25%) | |
| ≥2 | 902 (36%) | 978 (25%) | |
| Length of Stay | <0.0001 | ||
| 7–10 days | 848 (34%) | 1591 (40%) | |
| 11–15 days | 1307 (52%) | 1998 (51%) | |
| 16–21 days | 363 (14%) | 344 (9%) | |
| Antibiotic Switching (Yes) | 1467 (58%) | 1996 (51%) | <0.0001 |
*
Number of oral, inhaled and/or IV antibiotics administered on hospitalization day 5